OP002 Assessment of disease activity patterns during the first 10 years after diagnosis in a population-based Crohn’s disease cohort shows a quiescent disease course for a substantial proportion of the population

Wintjens, Dion S J; Bergey, François; Saccenti, Edoardo; Romberg‐Camps, Mariëlle; Oostenbrug, Liekele E.; Masclee, A.A.M.; Jonkers, Daisy; Pierik, Marie J.

doi:10.1093/ecco-jcc/jjx180.001

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In that cohort, 13% of patients experienced no further flare following diagnosis 1 . More recently, in a Dutch population‐based cohort of patients diagnosed 1991–2004, almost 30% of patients were categorised as quiescent 32 . Therefore, in population‐based cohorts a significant portion of CD patients seems to have a mild disease course with limited need to immunosuppressive therapy.…”

Section: Discussionmentioning

confidence: 98%

“…Age at diagnosis (per year) a 1. patients diagnosed 1991-2004, almost 30% of patients were categorised as quiescent. 32 Therefore, in population-based cohorts a significant portion of CD patients seems to have a mild disease course with limited need to immunosuppressive therapy. Better identification of these patients is important both in terms of our understanding of the disease as well as to stratify patients at diagnosis and avoid over-treating these patients with drugs with potential severe adverse events.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The use of 5‐aminosalicylate for patients with Crohn’s disease in a prospective European inception cohort with 5 years follow‐up – an Epi‐IBD study

et al. 2020

View full text Add to dashboard Cite

Background The lack of scientific evidence regarding the effectiveness of 5-aminosalicylate in patients with Crohn’s disease is in sharp contrast to its widespread use in clinical practice. Aims The aim of the study was to investigate the use of 5-aminosalicylate in patients with Crohn’s disease as well as the disease course of a subgroup of patients who were treated with 5-aminosalicylate as maintenance monotherapy during the first year of disease. Methods In a European community-based inception cohort, 488 patients with Crohn’s disease were followed from the time of their diagnosis. Information on clinical data, demographics, disease activity, medical therapy and rates of surgery, cancers and deaths was collected prospectively. Patient management was left to the discretion of the treating gastroenterologists. Results Overall, 292 (60%) patients with Crohn’s disease received 5-aminosalicylate period during follow-up for a median duration of 28 months (interquartile range 6–60). Of these, 78 (16%) patients received 5-aminosalicylate monotherapy during the first year following diagnosis. Patients who received monotherapy with 5-aminosalicylate experienced a mild disease course with only nine (12%) who required hospitalization, surgery, or developed stricturing or penetrating disease, and most never needed more intensive therapy. The remaining 214 patients were treated with 5-aminosalicylate as the first maintenance drug although most eventually needed to step up to other treatments including immunomodulators (75 (35%)), biological therapy (49 (23%)) or surgery (38 (18%)). Conclusion In this European community-based inception cohort of unselected Crohn’s disease patients, 5-aminosalicylate was commonly used. A substantial group of these patients experienced a quiescent disease course without need of additional treatment during follow-up. Therefore, despite the controversy regarding the efficacy of 5-aminosalicylate in Crohn’s disease, its use seems to result in a satisfying disease course for both patients and physicians.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

The use of 5‐aminosalicylate for patients with Crohn’s disease in a prospective European inception cohort with 5 years follow‐up – an Epi‐IBD study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Findings from Paper IV suggest that physicians had indeed identified CD patients that were at low risk for a severe disease course and treated them with 5-ASA. Previous studies have demonstrated that approximately 20% of CD patients show a quiescent disease course with minimal disease activity, as well as low rates of progression and surgery [27,55,118].…”

Section: Treatment Strategies In European Patients With Crohn's Disea...mentioning

confidence: 99%

Long‐term disease course, cost and prognosis of inflammatory bowel disease: epidemiological studies of a European and a Danish inception cohort

Burisch

2023

APMIS

View full text Add to dashboard Cite

Analysis of biomarkers and composite scores in IBD patients using probabilistic fuzzy systems

Adriaans

Almeida

Jonkers

et al. 2022

2022 IEEE International Conference on Fuzzy Systems (FUZZ-IEEE)

View full text Add to dashboard Cite

OP002 Assessment of disease activity patterns during the first 10 years after diagnosis in a population-based Crohn’s disease cohort shows a quiescent disease course for a substantial proportion of the population

Cited by 3 publications

References 0 publications

The use of 5‐aminosalicylate for patients with Crohn’s disease in a prospective European inception cohort with 5 years follow‐up – an Epi‐IBD study

The use of 5‐aminosalicylate for patients with Crohn’s disease in a prospective European inception cohort with 5 years follow‐up – an Epi‐IBD study

Long‐term disease course, cost and prognosis of inflammatory bowel disease: epidemiological studies of a European and a Danish inception cohort

Analysis of biomarkers and composite scores in IBD patients using probabilistic fuzzy systems

Contact Info

Product

Resources

About